Data Science Funding Announcements & Notices
Data science and informatics funding announcements and notices are available from NCI and NIH programs. Browse below for opportunities, requests for information, notices, and initiatives.
| Title Sort descending | FOA | Organization | Release Date | Expire Date | Purpose |
|---|---|---|---|---|---|
| Clinical Studies of Mental Illness (Collaborative R01) (Clinical Trial Optional) | PAR-23-050 | NIMH | This Funding Opportunity Announcement (FOA) seeks to support collaborative clinical studies, not involving treatment development, efficacy, or effectiveness trials. Primary areas of focus include… More | ||
| Clinical Trial Readiness for Rare Diseases, Disorders, and Syndromes (R03 Clinical Trial Not Allowed) | PAR-23-160 | NCATS | This Funding Opportunity Announcement (FOA) invites researchers to submit applications for support of clinical projects that address critical needs for clinical trial readiness in rare diseases. The… More | ||
| Clinical Trial Readiness for Rare Diseases, Disorders, and Syndromes (R21 Clinical Trial Not Allowed) | PAR-23-159 | NCATS | This Funding Opportunity Announcement (FOA) invites researchers to submit applications for support of clinical projects that address critical needs for clinical trial readiness in rare diseases. The… More | ||
| Clinical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U01 Clinical Trial Optional) | PAR-24-097 | NINDS | (Reissue PAR-21-058). The purpose of this Program Announcement (PAR) is to enable clinical validation of strong candidate biomarkers for neurological diseases and conditions. Specifically, the goal… More | ||
| Clinical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U44 Clinical Trial Optional) | PAR-24-096 | NINDS | The purpose of this Program Announcement (PAR) is to enable clinical validation of strong candidate biomarkers for neurological diseases and conditions. Specifically, the goal of this PAR is to… More | ||
| Co-infection and Cancer (R01 Clinical Trial Not Allowed) | PAR-23-055 | NCI | This initiative seeks to enhance our mechanistic and epidemiologic understanding of infection-related cancers, with a focus on the etiologic roles of co-infection in cancer. Preference will be… More |
||
| Co-infection and Cancer (R21 Clinical Trial Not Allowed) | PAR-23-056 | NCI | The purpose of this Funding Opportunity Announcement (FOA) is to enhance mechanistic and epidemiologic investigations addressing the roles of co-infection and cancer to shed light on presently… More | ||
| Cohort Studies of HIV/AIDS and Substance Use (U01 Clinical Trial Not Allowed) | RFA-DA-25-003 | NIDA | The purpose of this Notice of Funding Opportunity (NOFO) is to support the continuation of NIDA's HIV Cohorts Program, encouraging existing and new sites to address new emerging and/or high… More | ||
| Collaborative Opportunities for Multidisciplinary, Bold, and Innovative Neuroscience (COMBINE) (RM1 Clinical Trial Optional) | RFA-NS-23-027 | NINDS | Reissue of RFA-NS-22-011 to comply with DMSP changes. No changes to receipt dates or locus of review. This funding opportunity announcement (FOA) is designed to support integrated efforts of three or… More | ||
| Collaborative Program Grant for Multidisciplinary Teams (RM1 - Clinical Trial Optional) | PAR-23-077 | NIGMS | This funding opportunity announcement (FOA) is designed to support highly integrated research teams of three to six PD/PIs to address ambitious and challenging research questions that are important… More |